IO Biotech
Ole Maaløes Vej 3
Copenhagen N
2200
Denmark
Tel: 45-21-94-78-56
Website: http://www.iobiotech.com/
Email: mz@iobiotech.com
About IO Biotech
IO Biotech ApS was founded in December 2014 as a spin out from the Centre for Cancer Immune Therapy (CCIT), University of Copenhagen Herlev Hospital, Denmark.
YEAR FOUNDED:
December 2014
LEADERSHIP:
Fouinder and CEO: Mai-Britt Zocca
Founder and CSO: Mads Hald Andersen
44 articles with IO Biotech
-
IO Biotech Announces 2022 Fourth-Quarter and Year-End Results
3/14/2023
IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, announced financial results for the fourth quarter and year-ended December 31, 2022.
-
IO Biotech to Participate in March 2023 Investor Conferences
2/22/2023
IO Biotech today announced participation in two upcoming investor conferences.
-
IO Biotech Announces Appointment of Devin Smith as General Counsel
1/23/2023
IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® vaccine platform, today announced the appointment of Devin Smith as the company’s first General Counsel and Chief Compliance Officer.
-
IO Biotech Provides Business Update
1/9/2023
IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® vaccine platform, today provided a business update.
-
IO Biotech Announces Third Quarter Results for 2022
11/9/2022
IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced financial results for the quarter ending September 30, 2022.
-
IO Biotech Announces an Invited Oral Presentation and Two Poster Presentations with New Preclinical Data for Additional Pipeline Candidates at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
11/9/2022
IO Biotech (Nasdaq: IOBT), IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating anti-cancer therapies based on its proprietary T-win® technology, today announced details of the invited oral presentation and two poster presentations at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting.
-
IO Biotech Announces New Clinical Collaboration with Merck to Evaluate Neoadjuvant and Adjuvant IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) in a Phase 2, Multi-cohort Trial in Patients with Resectable Tumors
11/3/2022
IO Biotech announced that it has entered into a fourth clinical trial collaboration and supply agreement with Merck & Co., Inc., Rahway, NJ, USA, through a subsidiary.
-
IO Biotech to Participate in the 2022 Jefferies London Healthcare Conference
10/31/2022
IO Biotech announced that Mai-Britt Zocca, Ph.D., the company’s President and CEO, and Amy Sullivan, the company’s CFO, will be participating in a fireside chat and one-on-one investor meetings at the Jefferies London Healthcare Conference, taking place November 15 – 17, 2022.
-
IO Biotech Announces Invited Oral Presentation and Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
10/5/2022
IO Biotech announced an oral presentation and two poster presentations at the Society for Immunotherapy of Cancer’s 37th Annual Meeting (SITC 2022), to be held in Boston, Massachusetts and virtually on November 8-12, 2022.
-
Advances in immuno-oncology and adaptive cell therapy that began about a decade ago are enabling fresh, biology-driven approaches to bring therapeutic cancer vaccines closer to fruition.
-
IO Biotech to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
9/6/2022
IO Biotech announced that Mai-Britt Zocca, the company’s President and CEO, will be participating in a fireside chat and investor meetings at the Morgan Stanley 20th Annual Global Healthcare Conference, taking place September 12 – 14, 2022.
-
IO Biotech Announces Second Quarter Results for 2022
8/11/2022
IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced financial results for the quarter ending June 30, 2022.
-
IO Biotech to Participate in the 2022 BIO International Convention
6/6/2022
IO Biotech announced that the company will be participating at the 2022 BIO International Convention, taking place June 13 – 16, 2022, at the San Diego Convention Center in San Diego, California.
-
IO Biotech Announces Two Presentations at the American Society of Clinical Oncology Annual Meeting 2022
5/26/2022
IO Biotech (Nasdaq: IOBT), announced today two poster presentations highlighting clinical trials in progress with IO102-IO103 as an investigational agent in combination with pembrolizumab in metastatic solid tumors and in untreated, unresectable or metastatic melanoma at the American Society of Clinical Oncology (ASCO) Annual Meeting 2022.
-
IO Biotech to Participate in the Jefferies Healthcare Conference - May 23, 2022
5/23/2022
IO Biotech announced that the Company will be participating in the Jefferies Global Healthcare Conference, to be held June 8-10, 2022, in New York City.
-
Closing out the month of May, plenty of companies presented or announced clinical trial updates and news. Here’s a look.
-
IO Biotech Announces Initiation of Phase 3 Combination Trial of IO102-IO103 and KEYTRUDA® (pembrolizumab) as First-Line Treatment in Advanced Melanoma
5/18/2022
IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win ® technology platform, announced today that it has dosed the first patient in its Phase 3 IOB-013 / KN-D18 trial (NCT05155254).
-
IO Biotech Announces First Quarter Results for 2022
5/16/2022
IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced financial results for the quarter ended March 31, 2022.
-
IO Biotech Hosting Key Opinion Leader Webinar Series
4/22/2022
IO Biotech announced today that it will be hosting a series of key opinion leader (KOL) webinars.
-
It was a very busy week for clinical trial news, with much of it coming out of the American Association of Cancer Research Annual Meeting. Read on for details.